METTL3 can promote osteosarcoma development by directly increasing the m6A methylation level and the expression of lymphoid enhancer-binding factor 1(LEF1), and by activating the Wnt/β-catenin signaling pathway. This evidence concerns the gene LEF1 and osteosarcoma.